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Abstract 
Based on the directive from President George W. Bush to prepare the nation better for a possible smallpox attack, 
Florida enacted Operation Vaccinate Florida- Stage I (OVF I). Between February 10, 2003, and March 31, 2003, 
Florida vaccinated 4,434 individuals against smallpox. During this period a smallpox vaccine surveillance study 
was conducted in 18 counties in North Central Florida. The study was conducted via journal log, which participants 
completed daily by recording all symptoms, vaccination site stage development, and demographic information. The 
study included 350 vaccinees from Alachua, Baker, Bradford, Clay, Columbia, Dixie, Duval, Hamilton, Gilchrist, 
Lafayette, Levy, Flagler, Marion, Nassau, Putnam, Union, St. Johns, and Suwannee Counties. All symptoms 
experienced by study participants were normal and expected. Itching was experienced by 99.3% of the participants 
and site stage development was typical for the vaccinia virus. Naïve vaccinees had a longer mean vaccine site 
duration compared to non-naïve vaccinees. 
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Introduction 
After September 11, 2001 the United States 
government declared an increased need for 
bioterrorism awareness and training. A perceived 
threat of an intentional release of the smallpox virus 
was identified. In response to this apparent threat, 
President George W. Bush initiated a nationwide 
smallpox vaccination campaign. This campaign 
targeted persons that have the highest probability of 
coming into contact with the virus and include: 
healthcare workers, public health and hospital 
personnel and emergency response teams. Each 
participant in Florida chose voluntarily to receive the 
vaccine and was excluded if any contradictions (i.e. 
pregnancy, suppressed immune system, skin 
conditions, etc) existed.  
There are risks and side effects associated 
with the vaccine (Sibley, 2002). Some of these are 
considered non-serious reactions and are expected to 
occur. These expected non-serious reactions include: 
low grade fever, itching at the vaccination site, 
muscle aches, chills, nausea, fatigue, and joint pains 
(Frey, Couch, Tacket, et al, 2002; Sibley, 2002; 
Smallpox Fact Sheet, 2003). Other more severe 
reactions can occur and range from serious to life 
threatening. In previous vaccination sessions 
approximately 1,000 of every 1 million naïve 
vaccinees incurred a serious reaction that required 
medical treatment. These reactions included: 
erythema multiforme, inadvertent inoculation, and 
generalized vaccinia. It is estimated that 1 or 2 out of 
1 million vaccinees could die from the vaccine 
(Smallpox Fact Sheet, 2003).When the smallpox 
vaccine is properly administered as a preexposure 
prophylactic, it is 95%-98% effective in preventing 
smallpox (Sibley, 2002). The vaccine effectiveness 
decreases when administered as postexposure 
prophylaxis and vaccine effectiveness also decreases 
the longer the duration after exposure (Sibley, 2002).   
 Florida began its vaccination campaign 
(OFVI) in February 2003. A coalition of eighteen 
counties in North Central Florida agreed to have all 
smallpox vaccination participants complete a daily 
journal that would record the following facts: 
demographics, site stage duration, mild and severe 
reactions, loss of work, and medical care sought. The 
duration of the surveillance project was from 
February 10, 2003 to May 1, 2003 and included 350 
participants. 
 
Methods 
An 18-county consortium in North Central 
Florida was developed for this project and included: 
Alachua, Baker, Bradford, Clay, Columbia, Dixie, 
Duval, Hamilton, Gilchrist, Lafayette, Levy, Flagler, 
Marion, Nassau, Putnam, Union, St. Johns, and 
Suwannee counties. Each of the 18 volunteer 
counties offered the smallpox journal to all 
individuals receiving the smallpox vaccine during 
OVF1. Each county also designated an individual 
(nurse, doctor) to monitor the vaccinee recipients’ 
health status and aid in journal completion.  
The vaccine journal was developed based on 
previously documented reactions of the Dry Vax® 
smallpox vaccine manufactured by Wyeth 
Laboratories Inc., Marietta, Pennsylvania. The 
journal was developed to obtain information about 
vaccinees demographics, medical reactions to the 
vaccine, daily behavior modifications, and monitor 
stage development of the vaccine site. The smallpox 
vaccine journal was developed and approved by key 
stakeholders, including the Florida Department of 
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Health and directors of participating county health 
departments. Due to the time constraints of the 
vaccination program the vaccine journal was unable 
to be pre-tested. 
The journal was designed as a daily log to be 
completed by the individual vaccinee, site change 
nurse, or via telephone. The journal was completed 
daily until the scab fell off (point when no longer 
infectious to others). Each day the vaccinee would 
document all symptoms that occurred during the 
previous 24-hrs. Participants had the ability to record 
the occurrence of up to 37 symptoms each day (Table 
1).  Additional information was asked the day the 
scab fell off in “yes/no” format. Only symptoms 
experienced by over 10% of the vaccinees were 
included in the analysis.  
Participation in the study was limited to 
smallpox vaccine recipients living in the eighteen 
county consortium, who received the smallpox 
vaccine during OVFI, and who returned their journal 
log. Journals were made available at the time of 
vaccination and were either given directly to the 
vaccinee or kept in the vaccinees’ chart to be 
completed during the daily dressing check. A total of 
350 journals were returned from all eighteen 
counties. Participation in the study was voluntary.  
The study was conducted throughout the 
duration of OVF1, from February 10, 2003 to May 1, 
2003. The data collected in the journals were 
collected and analyzed using Epi Info 2002 and SPSS 
version 12.0. The response rate, frequencies, 
measures of central tendency and dispersion, and chi-
square tests for significance were calculated. An 
alpha level of 0.05 was used to determine 
significance. An index was used to better ascertain 
overall health effects on study participants. Overall 
health effects, characterized as ‘symptom-days’, the 
sum of all symptoms experienced in N number of 
days a vaccinee is followed, was calculated for each 
participant in the study group. Each symptom 
experienced was treated as an independent 
symptomatic day. This method accounts for 
differences in follow up time by treating each 
independent symptom frequency as 1 symptom-day 
(Figures 1 and 2).  
 
Results 
The sample population consisted of 350 
vaccinees out of a possible 472, yielding a response 
rate of 74.2% for the consortium and represented 
9.4% of Florida’s vaccinees in OVF I. Of the 
participants, 305 (89.4%) were white, 232 (66.5%) 
were female, and 253 (72.3%) ranged between 40-59 
years of age (Figure 3). 
 Of the 350 participants, 315 (90.0%) had 
successful takes, as assessed and documented by a 
nurse or physician. Of the 35 individuals who had 
unsuccessful takes, 13 (37.1%) chose to be 
revaccinated.  
 Of the 350 participants, 5 (6.8%) reported 
either missing work or school and 4 (5.5%) reported 
missing recreational activities. Six (2.0%) of the 
vaccinees sought medical attention during the post 
vaccination period. No vaccinee reported a personal 
contact (e.g. household member, sexual partner, or 
work contact) with lesions of undetermined etiology.  
 The mean vaccination length, the mean 
length of duration between vaccination and scab 
drop, among the study participants (N=350) was 
24.35 days and the range was 50-8 days.  The mean 
vaccination length for naïve vaccinees (n=15) was 
27.5 days and ranged from a minimum of 12 to a 
maximum of 50 days. The mean vaccination length 
among previous vaccinees (n=101) was 21.2 days 
and ranged from a minimum of 8 days to a maximum 
of 40 days.  There was a statistically significant 
difference in mean vaccination length between 
primary and secondary vaccinees (p= 0.001), with a 
difference of 6.3 days between means.   
The presence of a papule, the first stage of 
the vaccination site, occurred days 1-6; the mode 
occurred on day 2 with 52 (55.8%) vaccinees 
reporting papules (Figure 4.1). The vesicle, the 
second stage of the vaccine site, occurred from day 2-
7; the mode occurred on day 5 with 62 (53.2%) 
vaccinees reporting vesicles (Figure 4.2). The 
pustule, the third stage of the site development, was 
reported as occurring from days 3-19; the mode 
occurred on day 6 among the 64 (84.4%) vaccinees 
reporting pustules (Figure 4.3). The scab, the final 
stage of site development, was recorded as occurring 
from days 1-35; the mode occurred on day 14 with 58 
(89.7%) vaccinees reporting scabs (Figure 4.4). 
  The study group symptoms included: 
itching at vaccine site (99.3%), sore arm at vaccine 
site (37.3%), swollen lymph nodes (24.9%), 
headache (24.9%), redness >2/3inch at vaccine site 
(16.6%), fatigue (16.0%), allergic rash from tape 
dressing (14.2%), muscle aches (13%), and size of 
vaccine site >1/2inch (10.1%). Vaccinees reported 
the majority of symptoms between days 4-8 (Figure 
5). There was not a significant difference in the 
number of symptoms reported by the naïve vaccinees 
when compared to the number of symptoms reported 
by pre-vaccinees. The study participants reported a 
total of 564 symptom-days during the study period.  
 
Discussion 
  Past studies report that 21% of naïve 
individuals sought medical attention (Smallpox Fact 
Sheet, 2003). This current study followed both naïve 
and prevaccinated individuals. A low percentage 
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(6.8%) of the study participants missed work or 
school due to symptoms and only 2% sought medical 
attention. Reasons for the lower number of vaccinees 
seeking medical attention may include: better 
screening methods were used to eliminate individuals 
at a high risk for adverse reactions, primary vaccinees 
were discouraged from participating, and daily site 
checks by a medial professional may have reduced 
the number of patients that otherwise would have 
sought outside medical advice. 
 Participant’s vaccination sites were 
monitored daily for site stage development. The site 
stage developments observed in this study was 
similar to vaccination studies performed before 
smallpox eradication. In previous studies, papules 
formed on days 2-3, vesicles formed on day 3-5, 
pustules formed on day 5-7, and scabs formed on day 
10-12 (Sibley, 2002). In this post smallpox 
eradication study, the majority of the papules formed 
on day 1-3, the majority of vesicles formed on days 
2-7, the majority of the pustules formed on days 5-10 
and the majority of the scabs formed on days 9-22. 
 Naïve vaccinees experienced longer mean 
site duration than secondary vaccinees. The longer 
mean site duration among naïve participants is 
consistent to what would be expected 
immuniologically. 
 No unexpected reactions or symptoms were 
seen in the participants during this study. Allergic 
rashes from the vaccine site dressings occurred in 
14.2% of the patients.  Unlike previous vaccination 
studies the dressing sites were required to be covered 
with extreme diligence. This diligence in covering 
the vaccine site and disposing of soiled material 
properly demonstrated its effectiveness, as no 
secondary transmissions were identified during the 
study period.   
The investigators had a unique opportunity 
to observe how a sample of the civilian population in 
2003 would respond to the smallpox vaccine 
compared to previous populations. The daily log 
provided a means for monitoring the health status of 
vaccinees and provided insight into the site stage 
progression that has not been documented previously 
for 21st century population.  
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Table 1. List of Symptoms Presented to Vaccinees on Journal Log  
 
Headache                                                                          Rash anywhere on body                                                
Chills                                          Difficulty staying awake 
Fever                                  Difficulty breathing 
Muscle Aches                     Hoarseness 
Joint Paint                  Wheezing 
Loss of Appetite           Hives 
Fatigue                Paleness 
Swollen/tender lymph nodes                 Weakness 
Sore arm where vaccine given                       Fast heartbeat 
Swelling at site of vaccine >2/3inch                                Dizziness 
Redness at site of vaccine >2/3inch Eye infection 
Size of pustule >1/2inch                                      Inadvertent inoculation 
Problems sleeping                                   Generalized Vaccinia 
Allergic rash from tape/dressing                                  Erythema multiforme 
Itching at site of vaccine                              Eczema vaccinaum 
Sores anywhere else on body                                          Secondary infection at vaccine site 
Abdominal pain                                        Postvaccinal encephalitis 
Other                                                                               Death 
No symptoms 
  
 
Figure 1. Total Number of Symptom-Days Recorded for Prevaccinated Smallpox Vaccinees in an Eighteen 
County Region of North Central Florida, 2003. 
Distribution of Symptom-Days for Previously 
Vaccinated Persons
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Figure 2. Total Number of Symptom-Days Recorded for Primary Smallpox Vaccinees Among an Eighteen 
County Region of North Central Florida, 2003. 
Distribution of Symptom-Days for Primary 
Vaccinees
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Figure 3. Age range for Smallpox Vaccine Recipients in an Eighteen County Region of North Central Florida, 
2003 
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Figure 4. Smallpox Vaccine Site Development in an Eighteen County Region of North Central Florida, 2003 
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Figure 4.1 
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Figure 4.2 
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Figure 4.3 
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Figure 4.4   
 
 
Figure 5. ‘No Symptoms’ For All Vaccinees by Day Number for Eighteen County Region in North Central 
Florida, 2003  
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